ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in Durham, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Multiple Sclerosis
Sclerosis
Chronic Progressive Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Autoimmune Diseases
Neoplasm Metastasis
Cognitive Dysfunction

Multiple Sclerosis (MS) trials near Durham, NC, USA:

Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) (BEAT-MS)

of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized...

Enrolling
Secondary Progressive Multiple Sclerosis
Relapsing Multiple Sclerosis
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Biological: Best Available Therapy (BAT)

Phase 3

National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)

Durham, North Carolina, United States and 19 other locations

with Parkinson's disease (PD), essential tremor (ET), dystonia or multiple sclerosis (MS). These data will guide the desig...

Invitation-only
Multiple Sclerosis
Essential Tremor
Procedure: Therapeutic Stimulation Patterns
Procedure: Symptogenic Stimulation Patterns
Duke University
Duke University

Durham, North Carolina, United States and 2 other locations

To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS...

Enrolling
Multiple Sclerosis
Drug: Interferon beta-1a
Drug: Placebo capsule

Phase 3

Novartis
Novartis

Durham, North Carolina, United States and 107 other locations

This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple...

Active, not recruiting
Multiple Sclerosis, Relapsing-Remitting
Drug: Interferon beta type 1a
Drug: BIIB017 (peginterferon beta-1a)

Phase 3

Biogen
Biogen

Chapel Hill, North Carolina, United States and 64 other locations

This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofat...

Enrolling
Relapsing-Remitting Multiple Sclerosis
Drug: Disease modifying treatment (DMT)
Drug: Ofatumumab

Phase 4

Novartis
Novartis

Chapel Hill, North Carolina, United States and 36 other locations

This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early...

Active, not recruiting
Relapse Remitting Multiple Sclerosis
Drug: Ofatumumab

Phase 4

Novartis
Novartis

Raleigh, North Carolina, United States and 35 other locations

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...

Enrolling
Relapsing Multiple Sclerosis
Drug: Teriflunomide
Drug: Remibrutinib

Phase 3

Novartis
Novartis

Raleigh, North Carolina, United States and 220 other locations

for the overall conduct of the study at the site, confirmation of subject eligibility, routine study subject clinical management including for MS...

Active, not recruiting
Multiple Sclerosis
Drug: RPC-1063

Phase 3

Celgene
Celgene

Chapel Hill, North Carolina, United States and 60 other locations

) neo-antigen in subjects with relapsing multiple sclerosis (RMS).COVID-19 sub-study:The purpose of this research sub-study is to e...

Enrolling
Relapsing Multiple Sclerosis
Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV)
Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap)

Phase 3

Novartis
Novartis

Raleigh, North Carolina, United States and 301 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems